Atyr Pharma Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Atyr Pharma, Inc. on August 28, 2017, reporting events occurring on August 27 and August 31, 2017. The Company is a Delaware corporation headquartered in San Diego, California, and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses on a capital structure event rather than operational financial performance.
Material Changes
- Private Placement: On August 31, 2017, the Company closed a private placement with a select group of institutional investors, including Viking Global Investors, EcoR1 Capital, and Redmile Group. Certain investors are affiliated with the Company's directors and officers.
- Preferred Stock Designation: On August 28, 2017, the Company filed a Certificate of Designation with the Delaware Secretary of State, designating 2,285,952 shares of authorized unissued preferred stock as Class X Convertible Preferred Stock.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risk factors. The document serves to disclose the amendment to the Articles of Incorporation regarding the new Class X Convertible Preferred Stock and the closing of the associated private placement.
Key Facts for Investor Verification
- Verify the total capital raised in the private placement closed on August 31, 2017, as the specific dollar amount is not listed in this text.
- Review the full rights, preferences, and privileges of the Class X Convertible Preferred Stock in the referenced August 28, 2017 Form 8-K (Item 1.01) and Exhibit 3.1.
- Confirm the extent of ownership held by investors affiliated with the Company's directors and officers.